The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma: An Update

T Morris; Heather Oakervee; Paul Kettle; Aishleen Brunton; Gary Cook; Martin J. Leahy; Michael R Hamblin; Margaret Murray; H Enright; Mary McCloy; Peter O’Gorman; Kwee Yong; Tanya O’Shea; Rickin Popat; J Cavenagh

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2010

Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program

David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios A Dimopoulos, Sung‐Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson

Article2009

Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.

David S. Siegel, Sundar Jagannath, Sagar Lonial, Meletios A Dimopoulos, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Syed Rizvi, Kenneth C. Anderson

Chapter in a book2017

Treatment of Relapsed/Refractory Patients with Multiple Myeloma

Jacob P. Laubach, Philippe Moreau, Meletios A Dimopoulos, Paul G. Richardson

Article2022

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment

Meletios A Dimopoulos, Joseph Mıkhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl‐Goldstein, Paul G. Richardson

Article2021

Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos